PTIE Split History

PTIE (PTIE) has 1 split in our PTIE split history database. The split for PTIE took place on May 10, 2017. This was a 1 for 7 reverse split, meaning for each 7 shares of PTIE owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 142.857142857143 share position following the split.

When a company such as PTIE conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the PTIE split history from start to finish, an original position size of 1000 shares would have turned into 142.857142857143 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into PTIE shares, starting with a $10,000 purchase of PTIE, presented on a split-history-adjusted basis factoring in the complete PTIE split history.

Growth of $10,000.00 Without Dividends Reinvested
Start date:	06/11/2013
End date:	03/27/2019
Start price/share:	$17.50
End price/share:	$1.24
Dividends collected/share:	$0.00
Total return:	-92.91%
Average Annual Total Return:	-36.67%
Starting investment:	$10,000.00
Ending investment:	$708.63
Years:	5.79

About PTIE

Cassava Sciences engages in developing proprietary drugs for patients and healthcare professionals, and focuses its drug development efforts on disorders of the nervous system, such as chronic pain. Co.'s primary drug candidate, REMOXY, is a proprietary, abuse-deterrent, oral formulation of oxycodone developed to make oxycodone difficult to abuse yet provide pain relief. Co.'s other drug candidate, FENROCK, is a proprietary, abuse-deterrent skin patch to treat severe pain. In addition, Co. has worldwide rights to PTI-125, a small molecule drug candidate designed to treat Alzheimer's Disease and other neurological disorders. According to our PTIE split history records, PTIE has had 1 split.